Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
2021-01-07 22:09DeepakBhattMichaelSzarekBertramPittetal
四川生理科學(xué)雜志 2021年7期
Deepak L Bhatt,Michael Szarek,Bertram Pitt,et al.
Conclusions:In patients with diabetes and chronic kidney disease,with or without albuminuria,sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes,hospitalizations for heart failure,and urgent visits for heart failure than placebo but was associated with adverse events.
- 四川生理科學(xué)雜志的其它文章
- Flaviviruses Hit a Moving Target
- Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species
- Systematic analysis of binding of transcription factors to noncoding variants
- Spontaneous Chitin Accumulation in Airways and Age-Related Fibrotic Lung Disease
- Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
- Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer